Synageva's Sebelipase Alfa Phase 3 Data Selected For Oral Presentation

(RTTNews) - Synageva BioPharma Corp. (GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced that data from its Phase 3, global clinical study evaluating sebelipase alfa in children and adults with LAL Deficiency has been selected for oral presentation during the late-breaking session at The Liver Meeting, for the Study of Liver Diseases or AASLD, being held November 7-11 in Boston, MA.

Giving a brief description on Lysosomal Acid Lipase Deficiency or LAL D, the company said it is a life-threatening, underdiagnosed disease that causes progressive and multisystemic organ damage including hepatic cirrhosis and accelerated atherosclerosis that can lead to sudden and unpredictable clinical complications. LAL D often manifests in childhood but can be diagnosed at all ages with a simple blood test.